Welcome to episode 381 of the AI in Action podcast, the show where we break down the hype and explore the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives.
Powered by Alldus International, our goal is to share with you the insights of technologists and data science enthusiasts to showcase the excellent work that is being done within AI in North America and Europe.
Today's guest is Jesse Johnson, Head of Data Science and Data Engineering at Dewpoint Therapeutics in Boston, MA. Founded in 2018, Dewpoint Therapeutics is the first company to apply the emerging understanding of biomolecular condensates to drug discovery.
Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates, including cancer, neurodegeneration, infectious disease and metabolic disease. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into treatments for the toughest diseases.
In the episode, Jesse will discuss:
The interesting work they are doing in Biotechnology
The main objectives and goals of their work within Drug Discovery
Combining his life sciences skills with technical skills
An insight into the data science & engineering team
What’s in store for the near future at Dewpoint
His advice to those considering a career in life sciences
To find out more about all the great work happening at Dewpoint Therapeutics, check out the website www.dewpointx.com or follow them on LinkedIn and Twitter @dewpoint_tx. You can also connect with Jesse directly on LinkedIn or follow him on Twitter @jejomath.
What did you think of Jesse's podcast? Where do you see the future of AI and Data Science in the Healthcare industry heading over the next few years? We would love to hear your thoughts on this episode, so please leave a comment below.